Market Cap 226.85M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,606,500
Avg Vol 1,174,780
Day's Range N/A - N/A
Shares Out 66.53M
Stochastic %K 70%
Beta 1.81
Analysts Strong Sell
Price Target $12.67

Latest News on CRDF

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 21 days ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy


Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 3 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript


Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences


Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 10 months ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point


Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 10 months ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript